Takeda, Roivant Form Joint Venture for Women’s Health, Prostate Cancer; Takeda Transfers 2 Investigational Products

Takeda Pharmaceutical and Roivant Sciences Ltd. announced the formation of Myovant Sciences, a joint venture that will focus on the development of women’s health and prostate cancer solutions. Development and marketing rights to two products Takeda has been developing, relugolix...read more